Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
Mayra Shanley(The University of Texas MD Anderson Cancer Center), May Daher(The University of Texas MD Anderson Cancer Center), Jinzhuang Dou(The University of Texas MD Anderson Cancer Center), Sufang Li(The University of Texas MD Anderson Cancer Center), Rafet Başar(The University of Texas MD Anderson Cancer Center), Hind Rafei(The University of Texas MD Anderson Cancer Center), Merve Dede(The University of Texas MD Anderson Cancer Center), Joy Gumin(The University of Texas MD Anderson Cancer Center), Jezreel Pantaleόn Garcίa(The University of Texas MD Anderson Cancer Center), Ana Karen Nunez Cortes(The University of Texas MD Anderson Cancer Center), Shan He(The University of Texas MD Anderson Cancer Center), Corry M. Jones(The University of Texas MD Anderson Cancer Center), Sunil Acharya(The University of Texas MD Anderson Cancer Center), Natalie W. Fowlkes(The University of Texas MD Anderson Cancer Center), Donghai Xiong(The University of Texas MD Anderson Cancer Center), Sanjay K. Singh(The University of Texas MD Anderson Cancer Center), Hila Shaim(The University of Texas MD Anderson Cancer Center), S. Hicks(The University of Texas MD Anderson Cancer Center), Bin Liu(The University of Texas MD Anderson Cancer Center), Abhinav K. Jain(The University of Texas MD Anderson Cancer Center), Mohammed Fayyad Zaman(The University of Texas MD Anderson Cancer Center), Qi Miao(The University of Texas MD Anderson Cancer Center), Ye Li(The University of Texas MD Anderson Cancer Center), Nadima Uprety(The University of Texas MD Anderson Cancer Center), Enli Liu(The University of Texas MD Anderson Cancer Center), Luis Muniz-Feliciano(The University of Texas MD Anderson Cancer Center), Gary Deyter(The University of Texas MD Anderson Cancer Center), Vakul Mohanty(The University of Texas MD Anderson Cancer Center), Patrick Zhang(The University of Texas MD Anderson Cancer Center), Scott E. Evans(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(The University of Texas MD Anderson Cancer Center), Frederick F. Lang(The University of Texas MD Anderson Cancer Center), Ken Chen(The University of Texas MD Anderson Cancer Center), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center)
Cited by 79Open Access